Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Nonvalvular Atrial Fibrillation
Conditions
Nonvalvular Atrial Fibrillation
Trial Timeline
Dec 1, 2017 → Aug 30, 2019
NCT ID
NCT03374540About Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA)
Rivaroxaban (Xarelto, BAY59-7939) + Vitamin K antagonist (VKA) is a pre-clinical stage product being developed by Bayer for Nonvalvular Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT03374540. Target conditions include Nonvalvular Atrial Fibrillation.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03374540 | Pre-clinical | Completed |
| NCT01674647 | Phase 3 | Completed |
Competing Products
6 competing products in Nonvalvular Atrial Fibrillation
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AZD0837 + Vitamin-K antagonist at INR 2-3 + AZD0837 | AstraZeneca | Phase 2 | 52 |
| AZD0837 + VKA INR 2-3 | AstraZeneca | Phase 2 | 52 |
| Certoparin | Novartis | Phase 3 | 77 |
| Eliquis | Pfizer | Pre-clinical | 22 |
| Apixaban | Bristol Myers Squibb | Pre-clinical | 22 |
| Rivaroxaban 20 MG + Warfarin | Bayer | Approved | 82 |